Role of Non-Coding RNAs (lncRNA & miRNA) in Neurodegenerative Diseases
Neurodegenerative diseases damage nerve cells over time. Conditions like Alzheimer’s disease (AD), Parkinson’s disease (PD), and Amyotrophic Lateral Sclerosis (ALS) have no complete cure yet. Scientists now focus on non-coding RNAs (ncRNAs) as key players. These molecules do not make proteins but strongly control gene activity. Among them, microRNAs (miRNAs) and long non-coding RNAs (lncRNAs) stand out for their major roles in brain health and disease.
How miRNAs Influence Disease Progression
miRNAs are small RNA molecules that bind to messenger RNAs and reduce protein production. In neurodegenerative diseases, their levels often change.
In Alzheimer’s disease, certain miRNAs regulate amyloid-beta production and tau protein. For example, miR-107 targets BACE1 enzyme and reduces amyloid buildup. On the other hand, reduced miR-132 leads to higher tau phosphorylation and tangle formation.
In Parkinson’s disease, miRNAs affect alpha-synuclein aggregation and dopamine neuron loss. Dysregulated miRNAs also promote neuroinflammation and oxidative stress in both AD and PD. Researchers detect altered miRNA levels in blood, cerebrospinal fluid, and brain tissue, making them useful biomarkers.
Important Functions of lncRNAs
lncRNAs are longer RNA molecules that perform diverse tasks. They interact with DNA, proteins, and even miRNAs to control gene expression.
In Alzheimer’s, lncRNA BACE1-AS increases amyloid production. In Parkinson’s, specific lncRNAs regulate alpha-synuclein levels and neuronal survival. lncRNAs also influence mitochondrial function, autophagy, and inflammation across multiple diseases.
Moreover, lncRNAs act as sponges for miRNAs. This interaction creates complex regulatory networks that either protect neurons or accelerate damage.
Common Mechanisms Across Diseases
Non-coding RNAs affect shared pathways in neurodegeneration:
- They promote or reduce protein misfolding and aggregation.
- They control neuroinflammation and oxidative stress.
- They influence neuronal death and survival signals.
- They affect synaptic function and brain plasticity.
These RNAs also appear in exosomes, allowing them to travel between cells and spread disease signals or protective effects.
Potential as Biomarkers and Therapies
Doctors can detect changed miRNA and lncRNA levels in blood or saliva. This offers hope for early, non-invasive diagnosis.
For treatment, scientists develop miRNA mimics or inhibitors to restore balance. Antisense oligonucleotides target specific lncRNAs. Researchers also explore exosome-based delivery to carry these RNAs directly to the brain. Several approaches have reached clinical trials and show promise in slowing disease progression.
Challenges Ahead
Delivery to the brain remains difficult due to the blood-brain barrier. Off-target effects and stability issues need solutions. Moreover, researchers must validate findings across larger patient groups.
Despite these hurdles, non-coding RNAs open new doors. They help explain disease mechanisms and offer fresh strategies for diagnosis and treatment.
Future Outlook
Ongoing studies combine miRNAs and lncRNAs with other technologies like CRISPR and AI. This integrated approach may lead to personalized therapies for neurodegenerative diseases. As research advances rapidly, ncRNAs could transform how we understand, detect, and manage these challenging conditions in the coming years.
CMP Bio World 